Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ZAP70 | P43403 | 13/20 | 0.58 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.41 |
| ▸ | TYK2 | P29597 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.39 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1048229 | 0.89 | ZAP70 (0.68) | ZAP70MAPK14AURKAAURKBRIPK2 | |
| SCHEMBL12928885 | 0.88 | ZAP70 (0.62) | ZAP70TYK2 | |
| SCHEMBL12928894 | 0.86 | ZAP70 (0.58) | ZAP70TYK2 | |
| SCHEMBL1045824 | 0.86 | ZAP70 (0.67) | ZAP70MAPK14AURKAAURKBTYK2 | |
| SCHEMBL1049089 | 0.82 | ZAP70 (0.60) | ZAP70AURKAAURKBBRD4 | |
| SCHEMBL12928965 | 0.81 | ZAP70 (0.55) | ZAP70TYK2 | |
| SCHEMBL12929775 | 0.81 | ZAP70 (0.66) | ZAP70BRD4 | |
| SCHEMBL1049620 | 0.79 | ZAP70 (0.59) | ZAP70AURKAAURKBBRD4 | |
| SCHEMBL12928840 | 0.79 | ZAP70 (0.82) | ZAP70BRD4 | |
| SCHEMBL1044331 | 0.78 | ZAP70 (0.77) | ZAP70TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546370-B2 | Compounds and compositions as kinase inhibitors | IRM LLC (BM) | 2013-10-01 | — | — | US | disclosed |
| US-20110003798-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003798-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | FYN, SYK, RET | ZAP70 4/4885MAPK14 650/4885AURKA 843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.